Trial Profile
A randomized, double-blind study of a combination of amlodipine and irbesartan in patients with essential hypertension who insufficiently responded to irbesartan once daily
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jun 2016
Price :
$35
*
At a glance
- Drugs Amlodipine/irbesartan (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Sumitomo Dainippon Pharma
- 06 Jun 2016 New trial record